Green Thumb Industries vs. Curaleaf Holdings: Which Cannabis Stock Could Win Biggest From DEA Rescheduling?

DEA rescheduling cannabis to Schedule III could relieve 280E tax burdens, potentially lifting profitability and free cash flow for major U.S. operators. Green Thumb Industries appears better positioned with $1.2B in 2025 revenue, $348.4M normalized EBITDA, $295M operating cash flow, and a $344.5M cash balance, while Curaleaf offers higher upside leverage with $324.2M Q1 2026 revenue and $63.4M adjusted EBITDA. The article frames Green Thumb as the lower-risk winner and Curaleaf as the higher-risk, higher-reward play if federal reform improves industry economics.

Analysis

The real signal here is not that cannabis gets a valuation uplift from “reform,” but that the industry’s earnings quality should bifurcate sharply once 280E is no longer the binding constraint. Operators with already-positive GAAP earnings and excess cash generation should de-risk fastest because the market can underwrite their cash flows with lower discount rates, while levered names get a more dramatic EPS translation but remain hostage to refinancing and execution. That makes the winner set narrower than the headline implies: this is a balance-sheet and operating leverage story, not a pure sector beta trade.

Green Thumb’s edge is that it can turn tax relief into incremental capital allocation optionality rather than survival capital. Buybacks are especially important here because they create a visible, compounding claim on post-reform cash flows and can force multiple expansion if the market starts treating the company like a durable consumer staple instead of a distressed special situation. By contrast, Curaleaf’s larger scale and international exposure give it more torque if reform broadens access to capital, but that same leverage means any delay in policy implementation or a weaker-than-expected tax benefit could trap equity holders in a slow-recovery story.

The second-order implication is a relative-value rotation inside cannabis, not necessarily a clean sector-wide breakout. If the market starts pricing a lower effective tax rate but does not immediately assign legalization odds, the highest-quality U.S. operators should outperform the most levered names first, while international optionality becomes a longer-dated call on regulatory diffusion. A meaningful risk is that the market has already discounted a large part of the 280E relief narrative; if guidance revisions only modestly improve near-term EBITDA, the initial move could fade once investors realize cash taxes and capex still constrain free cash flow.

The catalyst path matters: near-term price action can happen in days as short interest and systematic flows react, but fundamental rerating likely takes multiple quarters of reported margin expansion. The key reversal trigger is political or legal friction that slows IRS/DEA implementation, or any sign that enforcement ambiguity preserves enough compliance cost to blunt the tax benefit. In that case, the trade should revert from outright long exposure to a quality-spread trade where the better balance sheet is still preferred but upside is more limited.

Key Decisions for Investors

• Long GTBIF / short CURLF for 1-3 months: express the view that the market will reward balance-sheet quality and buyback support before it fully prices Curaleaf's operating leverage; target 10-15% relative outperformance if reform timing stays clear.
• Sell CURLF out-of-the-money calls or use a call spread if already long: upside is real, but leverage and execution risk make the stock vulnerable to disappointment if tax savings take longer to show up than consensus expects.
• Add to GTBIF on any post-news pullback over the next 2-4 weeks: the stock has the cleanest path to multiple expansion because incremental cash flow can be deployed into repurchases rather than debt service.
• Avoid chasing broad cannabis baskets until implementation details are confirmed: the sector-wide move can fade if the IRS benefit is less immediate than traders assume; prefer single-name relative value over index beta.
• For higher-risk exposure, use CURLF Jan-2027 upside calls rather than stock: this preserves exposure to a larger policy-driven rerating while capping downside if reform stalls or financing conditions tighten.